The results of chemotherapy for extragonadal germ-cell tumors in the cisplatin era: The Memorial Sloan-Kettering Cancer Center experience (1975 to 1982)

Arthur Israel, G. J. Bosl, R. B. Golbey, W. Whitmore, N. Martini

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Thirty-eight patients with extragonadal germ-cell tumors treated at Memorial Sloan-Kettering Cancer Center (New York) between 1975 and 1982 received high-dose cisplatin-based chemotherapy. Complete response was achieved in 89% of patients with pure seminoma and all complete responders are alive without evidence of disease (median follow-up time, 29+ months). Complete response was achieved in only 41% (12 of 29) of patients with extragonadal nonseminomatous germ-cell tumors; only four patients are alive and free of disease (median survival time, 18 months). Although patients with extragonadal seminoma respond well with current cisplatin-based chemotherapy, minimal improvement in CR rates has been achieved in patients with extragonadal nonseminomatous tumors. Patients with extragonadal nonseminomatous germ-cell tumors have a relatively poor prognosis when compared to patients with primary testicular tumors and investigational trials of innovative therapy should be considered.

Original languageEnglish (US)
Pages (from-to)1073-1078
Number of pages6
JournalJournal of Clinical Oncology
Volume3
Issue number8
DOIs
StatePublished - Jan 1 1985
Externally publishedYes

Fingerprint

Germ Cell and Embryonal Neoplasms
Cisplatin
Drug Therapy
Neoplasms
Seminoma
Investigational Therapies
Testicular Neoplasms
Disease-Free Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{f861e8c99ae74a9aa95c4293d1721a29,
title = "The results of chemotherapy for extragonadal germ-cell tumors in the cisplatin era: The Memorial Sloan-Kettering Cancer Center experience (1975 to 1982)",
abstract = "Thirty-eight patients with extragonadal germ-cell tumors treated at Memorial Sloan-Kettering Cancer Center (New York) between 1975 and 1982 received high-dose cisplatin-based chemotherapy. Complete response was achieved in 89{\%} of patients with pure seminoma and all complete responders are alive without evidence of disease (median follow-up time, 29+ months). Complete response was achieved in only 41{\%} (12 of 29) of patients with extragonadal nonseminomatous germ-cell tumors; only four patients are alive and free of disease (median survival time, 18 months). Although patients with extragonadal seminoma respond well with current cisplatin-based chemotherapy, minimal improvement in CR rates has been achieved in patients with extragonadal nonseminomatous tumors. Patients with extragonadal nonseminomatous germ-cell tumors have a relatively poor prognosis when compared to patients with primary testicular tumors and investigational trials of innovative therapy should be considered.",
author = "Arthur Israel and Bosl, {G. J.} and Golbey, {R. B.} and W. Whitmore and N. Martini",
year = "1985",
month = "1",
day = "1",
doi = "10.1200/JCO.1985.3.8.1073",
language = "English (US)",
volume = "3",
pages = "1073--1078",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "8",

}

The results of chemotherapy for extragonadal germ-cell tumors in the cisplatin era : The Memorial Sloan-Kettering Cancer Center experience (1975 to 1982). / Israel, Arthur; Bosl, G. J.; Golbey, R. B.; Whitmore, W.; Martini, N.

In: Journal of Clinical Oncology, Vol. 3, No. 8, 01.01.1985, p. 1073-1078.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The results of chemotherapy for extragonadal germ-cell tumors in the cisplatin era

T2 - The Memorial Sloan-Kettering Cancer Center experience (1975 to 1982)

AU - Israel, Arthur

AU - Bosl, G. J.

AU - Golbey, R. B.

AU - Whitmore, W.

AU - Martini, N.

PY - 1985/1/1

Y1 - 1985/1/1

N2 - Thirty-eight patients with extragonadal germ-cell tumors treated at Memorial Sloan-Kettering Cancer Center (New York) between 1975 and 1982 received high-dose cisplatin-based chemotherapy. Complete response was achieved in 89% of patients with pure seminoma and all complete responders are alive without evidence of disease (median follow-up time, 29+ months). Complete response was achieved in only 41% (12 of 29) of patients with extragonadal nonseminomatous germ-cell tumors; only four patients are alive and free of disease (median survival time, 18 months). Although patients with extragonadal seminoma respond well with current cisplatin-based chemotherapy, minimal improvement in CR rates has been achieved in patients with extragonadal nonseminomatous tumors. Patients with extragonadal nonseminomatous germ-cell tumors have a relatively poor prognosis when compared to patients with primary testicular tumors and investigational trials of innovative therapy should be considered.

AB - Thirty-eight patients with extragonadal germ-cell tumors treated at Memorial Sloan-Kettering Cancer Center (New York) between 1975 and 1982 received high-dose cisplatin-based chemotherapy. Complete response was achieved in 89% of patients with pure seminoma and all complete responders are alive without evidence of disease (median follow-up time, 29+ months). Complete response was achieved in only 41% (12 of 29) of patients with extragonadal nonseminomatous germ-cell tumors; only four patients are alive and free of disease (median survival time, 18 months). Although patients with extragonadal seminoma respond well with current cisplatin-based chemotherapy, minimal improvement in CR rates has been achieved in patients with extragonadal nonseminomatous tumors. Patients with extragonadal nonseminomatous germ-cell tumors have a relatively poor prognosis when compared to patients with primary testicular tumors and investigational trials of innovative therapy should be considered.

UR - http://www.scopus.com/inward/record.url?scp=0021865401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021865401&partnerID=8YFLogxK

U2 - 10.1200/JCO.1985.3.8.1073

DO - 10.1200/JCO.1985.3.8.1073

M3 - Article

C2 - 2410574

AN - SCOPUS:0021865401

VL - 3

SP - 1073

EP - 1078

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 8

ER -